Volition is sponsoring a GenomeWeb webinar on Monday 26th February, titled ‘Neutrophils – Angels or Devils/The role of NETs in Sepsis and Organ Injury‘
The webinar will be led by Andrew Retter, Intensive Care Consultant, Guy’s and St. Thomas’ Hospital in London, England, and Terry Kelly, Chief Innovation Officer, VolitionRx.
About the webinar:
In this session, Andrew Retter of Guy’s and St. Thomas’ Hospital in London will provide an overview of the roles neutrophils play, from resting to activated; in primary and secondary haemostasis; and in thrombus formation and multi-organ failure. Terry Kelly, our Chief Innovation Officer, will share a new methodology for studying the chromatin dynamics in primary human neutrophils in a biologically relevant context. To conclude, Retter will present data from studies revealing how a NET biomarker might aid in the diagnosis and monitoring of disease progression.
The hour-long session is going to take place on Monday 26th February at 1:00 PM ET. If you would like to attend click here to register.
About the speakers:
Andrew Retter is an intensive care consultant at Guy’s and St. Thomas’ Hospital in London where he has worked as a consultant since 2014. Retter obtained his medical degree from St. George’s Hospital Medical School in 2001 and completed his postgraduate training in hematology and intensive care medicine at St. Thomas’ Hospital in London. He has subsequently worked as a consultant at St. Bartholomew’s Hospital before joining the team at Guy’s and St. Thomas’ Hospital.
Throughout his career, Retter has been passionate about using the latest technologies and innovations to improve patient outcomes. He has been involved in clinical trials and research studies and has published over 50 articles in peer-reviewed medical journals. His areas of expertise include the management of hematological malignancies and the management of complex coagulopathies, anticoagulation, and sepsis. In addition to his clinical work, Retter is also an accomplished educator and mentor. He teaches and trains medical students, residents, and fellows, and has served as a faculty member for educational courses. He is also a medical consultant to Volition.
Terry Kelly is our chief innovation officer and chief scientific officer for Volition America. She has over 15 years of experience in epigenetics, including developing novel technologies and seeing them through to commercialization. Her laboratory is based in San Diego, where they use a multiomics approach to understand the basic epigenetic mechanisms that underlie normal biology and how they are dysregulated by and contribute to, a variety of diseases including cancer and sepsis.
She received her doctorate in neuroscience from UCLA, completed a post-doctoral fellowship in cancer epigenetics at USC Norris Cancer Center, and has previous leadership roles in R&D and custom product and service development. She is an active member of the local community, including sitting on advisory boards.
If you would like to attend the webinar, please click here to register.
